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188Objective: Patients with complex cyanotic congenital heart disease and a bidirectional cavopulmonary connec-
tion who are not candidates for or had failed Fontan operation may experience progressive cyanosis. An axillary
arteriovenous anastomosis may be constructed to augment pulmonary blood flow. This report reviews our results
with this approach in this complex group of patients.
Methods: The records of patients with previous cavopulmonary connections who underwent a surgical anasto-
mosis between the axillary artery and the vein for palliation of severe progressive cyanosis were reviewed.
Results: Eleven patients were identified. The median age at the time of the axillary arteriovenous anastomosis
was 19.2 years (7.97–41.75 years). Seven patients were not candidates for the Fontan operation, and 4 patients
had failed Fontan surgery. Three of the anastomoses were constructed with a side-to-side technique, and 8 anas-
tomoses were constructed with a short interposition graft. Median fistula size was 5 mm (3–6 mm). There was
no operative mortality and 1 late death. Median survival was 2.85 years (0.01–7.22 years). All fistulae were patent
at follow-up. Median preoperative arterial oxygen saturation was 84% (80%–86%) and 82% (76%–88%)
at follow-up (P ¼ .38). Median preoperative hemoglobin was 18.5 g/dL (11.7–22.6 g/dL) and 19.2 g/dL
(14.6–22.6 g/dL) at follow-up (P ¼ .97). Median preoperative systemic ventricular ejection fraction was 51%
(27%–60%) and 46.5% (28%–60%) at follow-up (P ¼ 1). Significant functional improvement was seen in
only 1 patient.
Conclusions: In patients with complex cyanotic congenital heart disease who are not candidates for or had failed
Fontan operation, palliation with an axillary arteriovenous fistula did not improve cyanosis or polycythemia.
Functional outcome and ventricular ejection fraction did not improve or deteriorate. (J Thorac Cardiovasc
Surg 2011;141:188-92)The Fontan procedure provides good long-term palliation
for patients with a single ventricle and complex cyanotic
congenital heart disease.1,2 However, Fontan palliation
may not be achievable in all patients. Some patients who
have undergone previous cavopulmonary connections may
not be candidates for Fontan completion. There are also
those who may have had a failed Fontan surgery. The
superior cavopulmonary connection, with or without
additional sources of pulmonary blood flow, may provide
adequate palliation.3 However, increasing cyanosis resulting
from inadequate pulmonary arterial blood flow or develop-
ment of pulmonary arteriovenous fistulae may cause further
deterioration of their clinical condition.4 Construction of an
axillary arteriovenous (AAV) anastomosis has been used in
an effort to improve and stabilize their clinical condition.5-8e University of Alberta Stollery Children’s Hospital,a Edmonton, Alberta,
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The Journal of Thoracic and Cardiovascular SurgWe reviewed our experience with surgically created AAV
fistulae in patients with patent superior cavopulmonary
connections who were found not to be candidates for
completion of the Fontan procedure or patients who had
failed Fontan operation.
MATERIALS AND METHODS
Patients
We identified 11 patients with complex cyanotic congenital heart disease
with superior cavopulmonary connections (5 classic and 6 bidirectional) and
subsequent creation of an AAV fistula. Their medical records were reviewed
retrospectively. Institutional review board approval was obtained for this
study.
All patients had an AAV fistulae constructed between 2000 and 2007 at
the Mayo Clinic, Rochester. All patients were cyanotic and polycythemic
with related complications. Symptoms included fatigue or weakness
(n ¼ 7), headaches (n ¼ 3), and strokes or transient ischemic attacks
(n ¼ 5). Only 1 patient was using home oxygen. Four patients had known
pulmonary arteriovenous malformations diagnosed by catheterization
(n ¼ 3) and echocardiography (n ¼ 1).
Seven patients were not candidates for Fontan palliation. The reasons for
not proceeding with the Fontan pathway were multiple and complex and in-
volved significant clinical judgment. The principal reasons are given. One
patient had severe bilateral pulmonary artery hypoplasia, and 1 patient
had discontinuous central pulmonary arteries. One patient had pulmonary
hypertension with an ejection fraction (EF) of 52%, and he refused
heart–lung transplantation. Three patients had an EF of less than 50%
and were thought to have an overall high risk for the Fontan. One patientery c January 2011
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AAV ¼ axillary arteriovenous
EF ¼ ejection fraction
Hb ¼ hemoglobin
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Quin˜onez et al Congenital Heart Disease
C
H
Dhad an EF of 27% and was triaged to heart transplantation. The other 2
patients had an EF of 40% to 45%.
Four patients had undergone Fontan surgery. One patient still had her
Fontan circuit. This patient could not tolerate catheter device closure of
her fenestration. Two patients had their Fontan conduits taken down acutely
because of early postoperative hemodynamic deterioration and renal failure.
A final patient had the Fontan circuit taken down 9 years later because of
thrombus in the conduit and in an effort to relieve protein-losing enteropa-
thy. All other measures had failed, including Fontan revision (performed
elsewhere) and fenestration. This patient also had problems with gastroin-
testinal bleeding, making anticoagulation difficult.
Operation
All operations were performed under general anesthetic via an infracla-
vicular approach. The pectoralis major muscle was split along its fibers, and
the axillary artery and vein were isolated and controlled after systemic hep-
arinization. Care was taken to avoid injury to the brachial plexus. With the
exception of 1 patient, the ipsilateral side to the superior cavopulmonary
connection was chosen to maximize arterial flow through the connection.
The contralateral side was chosen in 1 patient because of an ipsilateral
subclavian vein obstruction. Imaging of the axillary artery and vein was ob-
tained by 1 or more methods, usually visualized at the time of echocardiog-
raphy or angiography. If there is any doubt about the patency of these
vessels, we consider a vascular ultrasound or venography.
Three AAV fistulae were performed using a direct side-to-side anasto-
mosis, and 8 AAV fistulae were performed with a polytetrafluoroethylene
(PTFE) graft, per the surgeons’ preference. The PTFE graft was kept as
short as possible to minimize resistance and avoid distortion of the artery
and vein (<10 mm). The median fistula size was 5 mm (range, 3–6 mm).
A 3-mm side-to-side fistula was used in an 8-year-old patient, and
a 3.5-mm graft was used in a 12.8-year-old patient. The rest of the fistulae
were 5 to 6 mm, and the patients’ ages ranged from 13.8 to 41.8 years. Six
fistulae were constructed on the left side. No patient had bilateral vena
cavae. The factors taken into consideration to determine the size of the fis-
tula were the patient’s size, the size of the axillary artery and vein, and the
potential risk of excessive volume loading the single functional ventricle.
The axillary vein distal to the fistula was not ligated.
Statistical Analysis
Median values for arterial oxygen saturation (SaO2), hemoglobin (Hb),
and systemic ventricular EF were compared using the rank sum method.RESULTS
The median age at the time of AAV fistula construction
was 19.2 years (range, 7.97–41.75 years) (Table 1). There
were 5 female patients. All had complex cyanotic congenital
heart disease. The median time interval from the cavopulmo-
nary connection to AAV fistula was 13.5 years (range,
0.11–41.32 years). Patients had a median of 4 operations
(range, 2–7) before AAV fistula creation.The Journal of Thoracic and CaThere were no operative deaths. None of the patients re-
quired admission to the intensive care unit. There were no
early complications. Ten patients were followed after hospi-
tal dismissal. The median follow-up period was 2.85 years
(range, 0.01–7.22 years). There was 1 late death from car-
diac and renal failure 6.33 years after the AAV fistula.
This patient had pulmonary hypertension and refused
heart–lung transplantation. He had a bidirectional cavopul-
monary connection. One patient was lost to follow-up be-
cause he returned to his home country.
Follow-up levels of SaO2 and Hb were available in 8 pa-
tients. The median preoperative SaO2 was 84% and was
not significantly different than the dismissal or the follow-
up SaO2 at 83% and 82%, respectively (P ¼ .41 and
P ¼ .38) (Figure 1). The median preoperative Hb level of
18.5 g/dL was also not significantly different compared
with the follow-up Hb level of 19.2 g/dL (P ¼ .97)
(Figure 2).
The median ventricular EF, measured by echocardiogra-
phy, in 7 patients with available data did not significantly
change in the follow-up period (51%–46.5%, P ¼ 1)
(Figure 3). When grouped into New York Heart Association
classes I/II and III/IV, 1 patient improved, 1 patient deterio-
rated, and the remaining patients were unchanged. Two pa-
tients were assessed for transplantation because of poor
ventricular function and significant symptoms. One refused
heart–lung transplantation and represents our single death in
the series. The other patient is alive and remains in stable
condition.
Four patients had further interventions during the follow-
up period. One patient had an additional central shunt to his
left pulmonary artery. Two patients had balloon dilation of
the right subclavian vein. In 1 of these patients, the fistula
was on the left side, opposite the side of the cavopulmonary
connection. Another patient had a balloon dilation and stent-
ing of the proximal right pulmonary artery. None of the
patients have had heart or heart–lung transplantation.
In 8 patients with available follow-up, the AAV fistulae
were demonstrated to be open by catheterization (n ¼ 2),
echocardiography (n ¼ 2), or physical examination
(n ¼ 4). Two patients had ipsilateral arm swelling. In 1 of
these patients, this was associated with venous thrombosis.
Another patient had ipsilateral arm numbness. One patient
had mild facial swelling and headaches. There were no other
complications attributed to the fistula.
DISCUSSION
Our findings did not demonstrate a clinically or statisti-
cally significant improvement in symptoms, SaO2, or Hb
levels after the creation of an AVV fistula in patients with
complex cyanotic congenital heart disease and cavopulmo-
nary connections. The AAV fistulae were constructed in
an effort to palliate and improve symptoms, cyanosis, and
polycythemia. These findings are not consistent with therdiovascular Surgery c Volume 141, Number 1 189
TABLE 1. Patient demographics and diagnoses
Patient Age (y) Diagnosis
1 8.0 Dextrocardia, situs inversus,
unbalanced AVSD, PA
2 12.8 DILV, PA, DORV
3 13.8 DILV, L-TGA, VSD
4 16.7 PA-IVS, TA
5 17.4 PA-IVS
6 19.2 PA-IVS
7 20.3 TA
8 22.6 Heterotaxy, single ventricle
9 36.8 Heterotaxy, DORV, discontinuous
pulmonary arteries
10 38.8 Criss-cross heart, D-TGA, AVSD
11 41.8 Univentricular heart, nonconfluent
pulmonary arteries
LV, Left ventricle; RV, right ventricle; DI, double inlet; DO, double outlet; PA, pulmo-
nary atresia; IVS, intact ventricular septum; D-TGA, dextro-transposition of the great
arteries; TA, tricuspid atresia; AVSD, atrioventricular septal defect; VSD, ventricular
septal defect.
Congenital Heart Disease Quin˜onez et al
C
H
Dconclusions of other published series.5-8 Nevertheless, we
did not observe significant clinical deterioration in this
group of patients. We do not know how the construction
of an AAV fistula may alter the modified natural history of
this difficult and complex group of patients.
In 1972, Glenn and Fenn5 reported supplementing pulmo-
nary blood flow with an AAV fistula in patients with previ-
ous classic cavopulmonary artery shunt. The Birmingham
Children’s Hospital group concluded that a brachial artery
to basilic vein fistula provides the same benefits of supple-
menting pulmonary blood flow with fewer complications.6
Kopf et al,7 from Yale University, observed improvements
in oxygen saturations after AAV fistula creation. Most re-
cently, Magee et al,8 from Toronto Sick Children’s Hospital,
reported the benefits in oxygen saturation and Hb levels after
an AVV fistula in a group of patients.
Technical factors may account for the lack of significant
improvement in our cohort. In our patients, the relative
size of the AVV fistula may have been inadequate to
augment pulmonary blood flow. The median fistula size inArterial Oxy
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FIGURE 1. SaO2 levels before and after axillar arteriovenous fistula in 8 patien
190 The Journal of Thoracic and Cardiovascular Surgour patients was 5 mm (3–6 mm), with a median patient
age of 19.2 years. The Toronto group describes a 6- to
7-mm AVV fistula in an overall younger group of patients
with a median age of 12.5 years.8 In 8 of our patients the fis-
tula was created with a PTFE graft, which may have added
resistance to flow. In the Toronto series, the fistulae were
made with a side-to-side anastomosis.8 Our recent and pre-
ferred technique is to use an PTFE graft between the artery
and the vein because it gives a more precise and consistent
fistula size compared with a side-to-side anastomosis. We
are reticent to use a large shunt because of the potential of
excessive volume loading of a single ventricle.
We did not ligate the distal axillary vein, as described by
the Toronto group. This may have decreased the amount of
effective blood flow through the cavopulmonary connection.
Ligation of the axillary vein distal to the fistula may be done
to prevent arm swelling. We have not found this to be a sig-
nificant problem, because only 2 of our patients had arm
swelling. Ligation of the vein may cause problems by further
increasing venous pressures in the head and neck causing
facial swelling and headaches. Ligation of the vein may
also lead to the development of large superficial venous col-
laterals to drain the arm, obviating the potential benefits of
ligation. We believe that the potential problems with ligation
of the distal axillary vein outweigh the theoretic benefits.
Effective palliation for patients with single ventricles can
be achieved with cavopulmonary connections, with or with-
out additional sources of pulmonary blood flow.3 This ap-
proach may be chosen when a patient is not a candidate
for Fontan palliation or has failed the Fontan. Comparable
survival outcomes have been published when comparing
this approach with the Fontan.9 However, progressive cya-
nosis can be a problem with the presence of a cavopulmonary
connection. The causes of failure are the development of de-
compressing systemic venous collaterals, the development
of pulmonary arteriovenous fistulae, or increased pulmonary
vascular resistance from the development of systemic-to-
pulmonary collaterals.4 Our older patients may have had
many of these problems, which may partially explain the
lack of observed benefit in our series.gen Saturation
issal SaO2 Late  Follow-up SaO2 Median 82 (Range 76, 88)
ts. Some values overlap between patients. SaO2, Arterial oxygen saturation.
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FIGURE 2. Hb level before and after AAV fistula in 8 patients. Hb, Hemoglobin.
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augment pulmonary blood flow through a cavopulmonary
connection. We found that the fistula can be made with
ease and without hospital morbidity or mortality. The extra-
thoracic approach obviates the need for repeat sternotomy in
this difficult patient population. The AAV fistula may
provide hepatic factor to the lung vasculature, thereby de-
creasing the quantity and development of pulmonary arterio-
venous fistulae.10 This could be a mechanism for the
improvement seen by other investigators. We do not have
the imaging data to confirm this finding. However, when
we analyzed the 4 patients with pulmonary arteriovenous
malformations, we did not see an improvement in their
SaO2. The AAV fistula may also increase the size of the pul-
monary arteries by adding pulsatility, thereby improving
pulmonary blood flow.11
There are potential disadvantages to the AAV fistula.
There is the risk of volume loading the single ventricle
with the additional blood flow.12 We did not observe dete-
rioration in ventricular function with the additional blood
flow from the fistula. Another problem may be dilation of
the caval vein and superior vena cava syndrome.12 Only
1 of our patients had mild facial swelling and headaches.
Finally, arm swelling was seen in only 2 patients in our
series.Ventricular Eject
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FIGURE 3. Ventricular EF before and after AA
The Journal of Thoracic and CaThe single death in our series was in a patient with com-
promised ventricular EF and significant functional impair-
ment. He refused heart–lung transplantation but lived more
than 6 years. There was reasonable continued survival in
our cohort. Our longest survivor has lived more than 7 years
after his fistula. We do not know whether the creation of an
AAV fistula alters the natural history of these complex pa-
tients, in relation to survival or future need for heart or
heart–lung transplantation. There is no available comparison
group because any patient who is symptomatic and signifi-
cantly cyanotic with no other correctible cause would
receive a fistula at the Mayo Clinic.
Four patients had additional interventions after their AAV
fistula surgery. All of these interventions sought to enhance
flow through the cavopulmonary connection or provide
additional blood flow through the pulmonary arteries. It is
important to continue to look for causes of desaturation in
these complex patients. The increased pressure in the supe-
rior vena cava after the creation of the AAV fistula may pre-
dispose to the development of decompressing systemic
venous collaterals. Optimal and unobstructed systemic
blood flow to the SVC should be maintained. The develop-
ment of pulmonary artery stenoses should be corrected. In
patients with a classic Glenn shunt, blood flow to the contra-
lateral lung should be ensured.ion Fraction
Late Follow-up EF Median 46.5 (Range 28, 60)
V fistula in 7 patients. EF, Ejection fraction.
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Our study is a retrospective analysis of a small cohort of
patients from a single institution. Because of the small num-
bers of patients, it is difficult to compare subgroups, such as
patients with classic versus bidirectional cavopulmonary
connections. The patients are heterogeneous and highly
complex. There is no similar group of patients available
for comparison.
CONCLUSIONS
In patients with complex cyanotic congenital heart disease
who are not candidates for or have failed a Fontan operation,
the construction of an AAV fistula may improve effective
pulmonary blood flow but does not improve cyanosis or
polycythemia. There was no deterioration in ventricular EF
or functional outcome with a reasonable continued survival.
The age of our patient cohort, the relative size of the AAV fis-
tula, and the technique of surgery may explain our findings.
The patients for whom this operation is considered present
infrequently. Furthermore, they have few, or no, options.
Despite our findings, we continue to offer this form of palli-
ation because we have found that these patients’ conditions
do not deteriorate with this operation. Each of these infre-
quent cases needs to be evaluated individually for any mod-
ification in our technical approach. Nevertheless, the use of
the fistula may stabilize a deteriorating condition, even if im-
provement is not observed. There are no data to prove this
contention, given the lack of a comparison group.192 The Journal of Thoracic and Cardiovascular SurgReferences
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